Replies to post #42979 on MultiCell Technologies Inc (MCET)

[TPX]

It is written about MCET and OXIS:

1. OXIS Holds Worldwide Exclusive Rights & U.S. Patent For Lead Therapy

OXIS further has licensed exclusive rights to three Antibody-drug conjugates (ADCs) through an agreement made in early 2015 with MultiCell Immunotherapeutics, Inc. MultiCell will prepare these ADCs for further evaluation as prospective therapeutics for the treatment of triple-negative breast cancer, as well as multiple myeloma and associated osteolytic bone disease.

Mr. Cataldo has extensive experience in the biotechnology sector having served as Chairman/CEO of several biotech companies including: MultiCell Technologies, Inc., Calypte Biomedical Corporation, and Senetek, PLC.

https://www.smarteranalyst.com/2016/07/13/one-small-biotech-stock-hold-key-curing-cancer/